Gossamer bio announces publication of torrey phase 2 results in the lancet respiratory medicine

San diego--(business wire)---- $goss--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah) and pulmonary hypertension associated with interstitial lung disease (ph-ild), today announced the publication of its torrey phase 2 study manuscript in the lancet respiratory medicine journal. the paper, titled "seralutinib in adults with pulmonary arterial hypertensio.
GOSS Ratings Summary
GOSS Quant Ranking